Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Benchmark Holdings ( (GB:BMK) ) has shared an update.
Benchmark Holdings reported its Q1 FY25 results, highlighting a transitional period as it moves towards completing the sale of its Genetics business and streamlining its operations. The company experienced a 30% decline in revenues from continuing operations compared to the previous year, primarily due to softness in shrimp markets and a change in product mix. Despite these challenges, the Health segment showed resilience, focusing on Salmosan® Vet. Benchmark is progressing with a new joint venture to develop a land-based model for Ectosan® Vet and CleanTreat®. The company plans to use proceeds from the Genetics sale to strengthen its balance sheet and return capital to shareholders.
More about Benchmark Holdings
Benchmark is a market-leading aquaculture biotechnology company focused on sustainability in aquaculture. It provides advanced nutrition and health products and solutions aimed at improving yield, growth, and animal health and welfare.
YTD Price Performance: -16.17%
Average Trading Volume: 138,483
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £207.6M
For a thorough assessment of BMK stock, go to TipRanks’ Stock Analysis page.